Fangzhou Inc. (6086) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 7.53M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.76
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: HK
• Employees: 488
• Sector: Technology
• Sector Strength: 84
• Industry: Drug Manufacturers - General
• EPS (TTM): -0.70
• Shares Outstanding: 1,340,267,500
• 10 Day Avg. Volume: 7,647,344
• 30 Day Avg. Volume: 7,529,498
• PEG Ratio: -2.15
• Price to Book (P/B): -10.52
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -308.71
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 27 Underperform
• Price Target: HK$4.00 ▲(1.01%Upside)

The overall score reflects Fangzhou Inc.'s troubling financial performance, which weighs heavily due to significant losses, high leverage, and cash flow challenges. Technical analysis provides a modestly positive outlook, but the valuation remains unattractive due to negative earnings. The absence of earnings call or corporate events data further limits the ability to identify potential mitigating factors.

Fangzhou Inc. Business Overview & Revenue Model

Company Description

Fangzhou Inc. provides online chronic disease management services in China. The company provides services through online chronic disease management platform to address the needs of patients with chronic disease, such as hypertension, cardiovascular and respiratory chronic diseases. It offers H2H services, including online medical consultation services, e-prescription, and prescription refill services through mobile application; and healthcare products through online retail pharmacy service platform, as well as operates hospitals and offline pharmacies. The company was founded in 2015 and is based in Guangzhou, China.

How the Company Makes Money

null

Fangzhou Inc. Financial Statement Overview

Summary

Fangzhou Inc. is facing significant financial challenges across all aspects of its financial statements. The company struggles with declining revenue, persistent losses, high leverage, and inadequate cash flow generation. These factors collectively highlight the company's precarious financial position and the urgent need for strategic improvements.

Income Statement

Fangzhou Inc. has experienced a declining revenue growth trend with a significant drop in profitability. The gross profit margin is relatively low and the company has been operating at a loss, as evidenced by negative EBIT and net income margins. A notable decline in net income suggests financial instability.

Balance Sheet

The balance sheet reveals high financial risk with a concerning debt-to-equity ratio due to negative equity. The company's liabilities significantly exceed its assets, and negative equity indicates potential solvency issues. The high leverage poses a substantial risk.

Cash Flow

Cash flow metrics indicate serious challenges, with operating cash flow being zero in the most recent period and an inability to generate positive free cash flow. The lack of operating cash flow compared to net income demonstrates inefficiency in cash management.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement		Total Revenue
2.71B	2.43B	2.56B	2.12B
	Gross Profit
515.94M	487.41M	441.20M	262.74M
	EBIT
-777.69M	-51.90M	-148.06M	-275.90M
	EBITDA
-739.87M	-174.76M	-127.78M	-260.07M
	Net Income Common Stockholders
-854.88M	-196.79M	-445.73M	-366.34M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
261.51M	146.32M	179.53M	103.56M
	Total Assets
664.09M	521.37M	582.57M	426.54M
	Total Debt
50.89M	49.72M	1.99B	1.70B
	Net Debt
-123.75M	-96.60M	1.81B	1.59B
	Total Liabilities
532.39M	2.42B	2.50B	2.07B
	Stockholders Equity
131.70M	-1.90B	-1.92B	-1.64B
Cash Flow		Free Cash Flow
15.63M	16.63M	-65.42M	-262.72M
	Operating Cash Flow
19.54M	22.28M	-59.28M	-246.43M
	Investing Cash Flow
-111.51M	16.42M	16.65M	-5.21M
	Financing Cash Flow
119.62M	-29.31M	125.88M	-12.77M

Fangzhou Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.96
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6086, the sentiment is Negative. The current price of 3.96 is below the 20-day moving average (MA) of 3.99, below the 50-day MA of 4.11, and below the 200-day MA of 4.97, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 44.43 is Neutral, neither overbought nor oversold. The STOCH value of 32.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6086.

Fangzhou Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$11.93B	10.60	-7.51%	3.00%	7.40%	-8.09%
6086	27 Underperform		―		―	―	―
MPNGF		$112.41B	19.76	23.82%	―	―	―
SNPTF		$9.09B	24.17	11.45%	0.82%	―	―
XIACF		$176.64B	40.57	14.98%	―	―	―
9999	81 Outperform	HK$639.34B	18.86	23.90%	2.07%	0.85%	6.37%
9888	75 Outperform	HK$240.23B	8.83	9.84%	―	-1.73%	32.35%

Fangzhou Inc. Corporate Events

Fangzhou Inc. Schedules Virtual Annual General Meeting for June 2025

Fangzhou Inc. has announced its upcoming Annual General Meeting, scheduled to be held virtually on June 19, 2025. The meeting will address several key agenda items, including the adoption of the company’s financial statements for the year ending December 31, 2024, the re-election of certain directors, and the re-appointment of KPMG as the company’s auditor. Additionally, resolutions will be considered to authorize the directors to manage the issuance of shares and related securities, which could impact the company’s capital structure and shareholder value.

Fangzhou Inc. Achieves 139% Profit Surge Amid Platform Growth

Fangzhou Inc. reported a significant 139% increase in adjusted net profit for 2024, attributed to technology enhancements and improved operating efficiency. The Jianke Platform experienced substantial growth, with 49.2 million registered users and a 20% increase in average monthly active users. The company’s integration with the social healthcare insurance system marks a strategic advancement, potentially enhancing its market positioning and stakeholder engagement.

Fangzhou Inc. Schedules Board Meeting to Review Annual Results

Fangzhou Inc. has announced that its board of directors will convene on March 21, 2025, to review and approve the company’s annual results for the fiscal year ending December 31, 2024. The meeting will also consider the declaration of a final dividend and address other business matters, signaling potential financial developments for stakeholders.